RGFP 966

CAS No. 1357389-11-7

RGFP 966( RGFP966 | RGFP 966 | RGFP-966 )

Catalog No. M11466 CAS No. 1357389-11-7

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 75 In Stock
2MG 42 In Stock
5MG 68 In Stock
10MG 107 In Stock
25MG 188 In Stock
50MG 291 In Stock
100MG 477 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RGFP 966
  • Note
    Research use only, not for human use.
  • Brief Description
    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
  • Description
    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RGFP966 | RGFP 966 | RGFP-966
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1357389-11-7
  • Formula Weight
    362.4
  • Molecular Formula
    C21H19FN4O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥100mM
  • SMILES
    O=C(NC1=CC=C(F)C=C1N)/C=C/C2=CN(C/C=C/C3=CC=CC=C3)N=C2.
  • Chemical Name
    (E)-N-(2-amino-4-fluorophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Malvaez M, et al. PNAS, 2013, 110(7), 2647-2652.
molnova catalog
related products
  • Suprastat

    Suprastat is an HDAC6 inhibitor used in silico simulations.

  • Droxinostat

    Droxinostat (NS-41080) is a selective HDAC inhibitor with IC50 of 16.9, 2.47 and 1.46 uM for HDAC3, HDAC6 and HDAC8, respectively.

  • ACY-241

    ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.